August 20, 2026

Amylyx $500.2M Upsized Offering at $35.50, Mankind-Chenan Insulin Deal, Tolerance Bio Licenses NT-I7, Network Bio $50M AI Launch

Amylyx upsizes offering to $500.2M at $35.50/share. Mankind-Chenan insulin India deal. Tolerance Bio licenses NT-I7 IL-7 fusion. Network Bio $50M launch.

4 stories · Covering industry

Editor's Note

Thursday's peptide news is capital markets and licensing heavy following Monday's Amylyx LUCIDITY win. Amylyx Pharmaceuticals (NASDAQ: AMLX) upsized its underwritten public offering to $500.2 million from the initial $350 million announcement, pricing 14,090,000 shares at $35.50 per share Wednesday August 19 with expected closing August 21 and an underwriter 30-day option for an additional 2,113,500 shares that would bring total raise capacity to roughly $575 million; the raise funds avexitide commercial launch preparation, NDA submission activities (planned end of 2026), and AMX0318 IND-enabling studies. Indian drugmaker Mankind Pharma announced Thursday August 20 the acquisition of exclusive Indian rights to two insulin analogue peptides from Chinese biopharmaceutical firm Chongqing Chenan Biopharmaceutical, including insulin degludec (a Novo Nordisk Tresiba equivalent, the ultra-long-acting basal insulin analogue with roughly 42-hour duration of action) and the insulin degludec plus insulin aspart fixed-combination (Novo Nordisk Ryzodeg equivalent, combining basal and rapid-acting insulin components), broadening Mankind's diabetes commercial franchise in the world's largest diabetes patient population. Tolerance Bio announced an exclusive $260 million license agreement with South Korean biotech NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), a clinical-stage long-acting IL-7 (interleukin-7) fusion protein, for certain thymus-related indications in the Americas and Europe, with Phase 2 trial initiation planned for HIV immunological non-response as a model of accelerated immune aging. And Network Bio launched Thursday with $50 million in financing to build AI models trained on human biological data for drug discovery, extending the broader AI-driven peptide and biologic discovery ecosystem that also includes PeptiDream's PDPS platform, Insilico Medicine's Pharma.AI, Aizen Therapeutics' DaX foundation model, and Isomorphic Labs.

Industry

Amylyx Pharmaceuticals (NASDAQ: AMLX) Upsized Its Underwritten Public Offering to $500.2 Million From the Initial $350 Million Announcement, Pricing 14,090,000 Shares of Common Stock at $35.50 per Share Wednesday August 19, 2026 With Expected Closing August 21 and an Underwriter 30-Day Option for an Additional 2,113,500 Shares That Would Bring Total Raise Capacity to Roughly $575 Million (Before Underwriting Discounts and Commissions); Use of Proceeds: Avexitide (Exendin 9-39, a Peptide GLP-1 Receptor Antagonist) Commercial Launch Preparation Following the Monday LUCIDITY Phase 3 Win, NDA Submission Activities (Planned End of 2026), AMX0318 IND-Enabling Studies, and General Corporate Purposes; New Investors Will Experience Substantial Immediate Dilution Relative to the Public Offering Price, With 111,368,283 Shares Outstanding as of June 30, 2026 Now Growing by 12.6% on Base Offering and 14.5% Including the Overallotment

Amylyx Pharmaceuticals (NASDAQ: AMLX) upsized its underwritten public offering to $500.2 million from the initial $350 million announcement, pricing 14,090,000 shares of common stock at $35.50 per share Wednesday August 19, 2026. Expected closing: August 21, 2026, subject to customary closing conditions. Underwriter 30-day option: additional 2,113,500 shares at the same price less underwriting discounts and commissions, which would bring total raise capacity to roughly $575 million if fully exercised. Use of proceeds: avexitide (exendin 9-39, a peptide GLP-1 receptor antagonist) commercial launch preparation following the Monday August 18 LUCIDITY Phase 3 primary endpoint hit (55% reduction in composite Level 2/3 hypoglycemic events, p=0.000003, in post-bariatric hypoglycemia), NDA submission activities planned for end of 2026, AMX0318 (long-acting GLP-1 receptor antagonist candidate) IND-enabling studies with IND filing targeted 2027, and general corporate purposes. Dilution: as of June 30, 2026, Amylyx reported 111,368,283 shares outstanding; the 14.09 million new shares represent roughly 12.6% dilution on the base offering and 14.5% dilution including the underwriter overallotment. The upsize from $350M to $500.2M reflects the strong demand generated by the LUCIDITY win and the analyst reception (Guggenheim $55 PT, Mizuho $30, H.C. Wainwright $20, Seeking Alpha Strong Buy upgrade). Amylyx also expanded its board of directors as part of the capital markets round.

#amylyx-pharmaceuticals #amlx #500-2-million-offering #upsized-offering #35-50-per-share #14-09-million-shares #avexitide-commercial-preparation #nda-end-2026 #amx0318-ind-2027 #dilution

Industry

Indian Drugmaker Mankind Pharma Announced Thursday August 20, 2026 the Acquisition of Exclusive Indian Rights to Two Insulin Analogue Peptides From Chinese Biopharmaceutical Firm Chongqing Chenan Biopharmaceutical, Including Insulin Degludec (a Novo Nordisk Tresiba Equivalent, the Ultra-Long-Acting Basal Insulin Analogue With Approximately 42-Hour Duration of Action That Provides Once-Daily Basal Coverage With Reduced Nocturnal Hypoglycemia Compared to Insulin Glargine) and the Insulin Degludec Plus Insulin Aspart Fixed-Combination (Novo Nordisk Ryzodeg Equivalent, Combining Basal and Rapid-Acting Insulin Components in a Single Injection); Financial Terms Were Not Disclosed; The Agreement Strengthens Mankind's Diabetes Commercial Franchise in the World's Largest Diabetes Patient Population With Approximately 101 Million Adults Living With Diabetes in India as of 2023

Indian drugmaker Mankind Pharma announced Thursday August 20, 2026 the acquisition of exclusive Indian rights to two insulin analogue peptides from Chinese biopharmaceutical firm Chongqing Chenan Biopharmaceutical. Products in scope: insulin degludec (a Novo Nordisk Tresiba equivalent), an ultra-long-acting basal insulin analogue with approximately 42-hour duration of action that provides once-daily basal coverage with reduced nocturnal hypoglycemia compared to insulin glargine; and the insulin degludec plus insulin aspart fixed-combination (Novo Nordisk Ryzodeg equivalent), combining basal and rapid-acting insulin components in a single injection for patients requiring both basal glycemic control and prandial coverage. Financial terms were not disclosed. The agreement strengthens Mankind's diabetes commercial franchise in the world's largest diabetes patient population; India has approximately 101 million adults living with diabetes as of 2023 per International Diabetes Federation estimates, with the burden projected to reach 134 million by 2045. Both molecules are peptides: insulin degludec is a 51-amino-acid peptide analogue with a hexadecanedioic acid attachment at position B29 that enables the ultra-long-acting profile through multi-hexameric self-association at the injection site. The Chinese-Indian licensing structure follows the growing pattern of Chinese biopharmaceutical companies (Chongqing Chenan, Hengrui, Innovent) partnering with regional distribution and manufacturing partners in India, Southeast Asia, and Latin America to scale peptide-based diabetes and metabolic drug access in emerging markets.

#mankind-pharma #chongqing-chenan-biopharmaceutical #insulin-degludec #insulin-degludec-aspart #insulin-analogue #india-licensing #tresiba-biosimilar #ryzodeg-biosimilar #diabetes #peptide-manufacturing #emerging-markets

Industry

Tolerance Bio Announced an Exclusive $260 Million License Agreement With South Korean Biotech NeoImmuneTech for the Development and Commercialization of Efineptakin Alfa (NT-I7), a Clinical-Stage Long-Acting IL-7 (Interleukin-7) Fusion Protein, for Certain Thymus-Related Indications in the Americas and Europe; Tolerance Bio Plans to Initiate Phase 2 Clinical Trials Evaluating Efineptakin Alfa for the Enhancement of Thymic Function, With HIV Immunological Non-Response (a Condition Where Patients on Effective Antiretroviral Therapy Fail to Rebuild CD4+ T Cell Counts and a Model of Accelerated Immune Aging) Expected to Be Among the Initial Indications Evaluated; The Agreement Marks Tolerance Bio's Transition to a Clinical-Stage Biotechnology Company, Advancing Efineptakin Alfa in New Indications Aligned With Its Strategy to Preserve Thymic T Cell Output and Enhance Immune Resilience in Immunologically Vulnerable Populations

Tolerance Bio announced an exclusive $260 million license agreement with South Korean biotech NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), a clinical-stage long-acting IL-7 (interleukin-7) fusion protein, for certain thymus-related indications in the Americas and Europe. Mechanism: IL-7 is an immune cytokine that supports T cell development in the thymus and maintenance of memory T cell populations in peripheral tissues. Efineptakin alfa combines the IL-7 cytokine with a fusion partner that extends the half-life from IL-7's native short duration (minutes to hours) to a long-acting profile supporting less-frequent dosing. Tolerance Bio plans to initiate Phase 2 clinical trials evaluating efineptakin alfa for the enhancement of thymic function, with HIV immunological non-response as the lead indication. HIV immunological non-response describes patients on effective antiretroviral therapy who fail to rebuild CD4+ T cell counts to normal levels; it represents a model of accelerated immune aging and provides an established regulatory pathway for demonstrating thymic-function benefit. Additional planned indications include age-related immunosenescence and immune reconstitution after stem cell transplantation. The agreement marks Tolerance Bio's transition to a clinical-stage biotechnology company. Efineptakin alfa has previously been studied in oncology combinations with Merck's Keytruda, BMS's Opdivo, and other checkpoint inhibitors under NeoImmuneTech's development; the Tolerance Bio license refocuses the asset on non-oncology thymus-preservation indications where the long-acting IL-7 mechanism produces broader clinical benefit.

#tolerance-bio #neoimmunetech #efineptakin-alfa #nt-i7 #interleukin-7 #il-7-fusion-protein #260-million-license #thymic-function #hiv-immunological-non-response #immune-resilience #immune-aging

Industry

Network Bio Launched Thursday August 20, 2026 With $50 Million in Series A Financing to Build AI Models Trained on Human Biological Data for Drug Discovery, Adding to the Rapidly Expanding AI-Driven Peptide and Biologic Discovery Ecosystem That Also Includes PeptiDream's PDPS Platform (Constrained Cyclic Peptide Focus, Partnerships With Novartis, Merck, Genentech, AbbVie, Eli Lilly), Insilico Medicine's Pharma.AI (31 Developmental Candidates, $2.75 Billion Lilly Deal + $2.5 Billion SK Deal + Takeda Collaboration), Aizen Therapeutics' DaX Foundation Model (August 15 Deal With San Diego Public Biotech Worth Up to $100 Million per Target for Oral Peptide Therapeutics), and Isomorphic Labs (Google DeepMind Spinout With AlphaFold-Derived Structural Modeling); The AI Drug Discovery Category Has Accumulated More Than $8 Billion in Partnership Deal Value Across 2026 to Date

Network Bio launched Thursday August 20, 2026 with $50 million in Series A financing. Company thesis: build AI models trained on human biological data (spanning multi-omics, single-cell sequencing, and functional genomics datasets) for drug discovery across multiple therapeutic areas. The launch adds to the rapidly expanding AI-driven peptide and biologic discovery ecosystem that also includes PeptiDream's PDPS platform (Kawasaki-based, constrained cyclic peptide focus with active partnerships across Novartis, Merck, Genentech/Roche, AbbVie, Bristol Myers Squibb, and Eli Lilly), Insilico Medicine's Pharma.AI (31 developmental candidates on the platform, $2.75 billion Lilly collaboration March 2026, $2.5 billion SK Biopharmaceuticals deal June 2026, Takeda strategic collaboration July 2026), Aizen Therapeutics' DaX foundation model (August 15 deal with San Diego public biotech worth up to $100 million per target for oral peptide therapeutics, non-canonical amino acid chemical space at 10x traditional scale), and Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling for target validation and small-molecule design). The AI drug discovery category has accumulated more than $8 billion in partnership deal value across 2026 to date, with peptide-focused platforms capturing a substantial share of the total given the growth of the peptide therapeutic modality across obesity (GLP-1 class), rare disease (setmelanotide, palopegteriparatide, vosoritide, avexitide), and oncology (peptide-drug conjugates, radioligand therapies). Network Bio's Palo Alto location adds to the West Coast AI biotech cluster that also includes Recursion, Insitro, and Isomorphic Labs.

#network-bio #50-million-series-a #ai-drug-discovery #human-biological-data #peptidream #insilico-medicine #aizen-therapeutics #isomorphic-labs #ai-peptide-discovery #palo-alto-biotech #8-billion-partnership-deals